(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Makovski V et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. 2012 Int. J. Cancer pmid:21500191
Yaari-Stark S et al. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. 2010 Int. J. Cancer pmid:19998334
Biran A et al. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. 2011 Int. J. Cancer pmid:20473860
Egozi Y et al. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. 1999 Int. J. Cancer pmid:10074926
Smalley KS and Eisen TG Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. 2003 Int. J. Cancer pmid:12673674
Yue W et al. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. 2005 Int. J. Cancer pmid:15957161
Blum R et al. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. 2006 Int. J. Cancer pmid:16496386
Beiner ME et al. Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. 2006 Jan-Feb Int. J. Gynecol. Cancer pmid:16515591
Davey KG and Sommerville RI Molting in a parasitic nematode, Phocanema decipiens. VII. The mode of action of the ecdysial hormone. 1974 Int. J. Parasitol. pmid:4853251
Tofts J and Meerovitch E The effect of farnesyl methyl ether, a mimic of insect juvenile hormone, on Hymenolepis Diminuta in vitro. 1974 Int. J. Parasitol. pmid:4822487
Davey KG Molting in a parasitic nematode, Phocanema decipiens. VI. The mode of action of insect juvenile hormone and farnesyl methyl ether. 1971 Int. J. Parasitol. pmid:5161204
Laheru D et al. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. 2012 Invest New Drugs pmid:22547163
Eglin D et al. Farnesol-modified biodegradable polyurethanes for cartilage tissue engineering. 2010 J Biomed Mater Res A pmid:19191318
Kraitzer A et al. Mechanisms of antiproliferative drug release from bioresorbable porous structures. 2013 J Biomed Mater Res A pmid:23065767
Unnanuntana A et al. The effects of farnesol on Staphylococcus aureus biofilms and osteoblasts. An in vitro study. 2009 J Bone Joint Surg Am pmid:19884443
Kubesová A et al. Separation of attogram terpenes by the capillary zone electrophoresis with fluorometric detection. 2010 J Chromatogr A pmid:20933239
Cagliero C et al. Analysis of essential oils and fragrances with a new generation of highly inert gas chromatographic columns coated with ionic liquids. 2017 J Chromatogr A pmid:28343686
Lee H et al. Characterization of (E,E)-farnesol and its fatty acid esters from anal scent glands of nutria (Myocastor coypus) by gas chromatography-mass spectrometry and gas chromatography-infrared spectrometry. 2007 J Chromatogr A pmid:17709112
Kang L et al. SMGA gels for the skin permeation of haloperidol. 2005 J Control Release pmid:15975680
Novák VJ Morphogenetic analysis of the effects of juvenile hormone analogues and other morphogenetically active substances on embryos of Schistocerca gregaria (Forskål). 1969 J Embryol Exp Morphol pmid:5765790
Woodard B et al. 3D-QSAR of fungal quorum-sensing inhibiting analogs of farnesol. 2007 Mar-Apr J Environ Sci Health B pmid:17454380
Jahangir T and Sultana S Benzo(a)pyrene-induced genotoxicity: attenuation by farnesol in a mouse model. 2008 J Enzyme Inhib Med Chem pmid:18618320
Rüegg T et al. 3-Farnesyl-2-hydroxybenzoic acid is a new anti-Helicobacter pylori compound from Piper multiplinervium. 2006 J Ethnopharmacol pmid:16266794
Huang J et al. Electrohydrodynamic deposition of nanotitanium doped hydroxyapatite coating for medical and dental applications. 2011 J Mater Sci Mater Med pmid:21243517
Jamalian A et al. Chemical composition and antifungal activity of Matricaria recutita flower essential oil against medically important dermatophytes and soil-borne pathogens. 2012 J Mycol Med pmid:23518164
Gregus P et al. Ultra high performance liquid chromatography tandem mass spectrometry analysis of quorum-sensing molecules of Candida albicans. 2010 J Pharm Biomed Anal pmid:20580513
Teshima K and Kondo T Analytical method for determination of allylic isoprenols in rat tissues by liquid chromatography/tandem mass spectrometry following chemical derivatization with 3-nitrophtalic anhydride. 2008 J Pharm Biomed Anal pmid:18313250
Wang Z et al. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. 2003 Jan-Apr J Pharm Pharm Sci pmid:12753732
Kraitzer A et al. Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro. 2011 J Pharm Sci pmid:20623695
Abu-Mustafa EA et al. Natural coumarins. XII. Umbelliprenin, a constituent of ammi majus L. fruits. 1971 J Pharm Sci pmid:5125784
Wartenberg D et al. Proteome analysis of the farnesol-induced stress response in Aspergillus nidulans--The role of a putative dehydrin. 2012 J Proteomics pmid:22634043
Riely GJ et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. 2011 J Thorac Oncol pmid:21847063
Okazaki S et al. [A 13-week subcutaneous toxicity study of prednisolone farnesylate (PNF) in rats]. 1992 J Toxicol Sci pmid:1293320
Nagashima Y et al. [A 13-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 5 weeks]. 1992 J Toxicol Sci pmid:1293321
Nagashima Y et al. [A 52-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 8 weeks]. 1992 J Toxicol Sci pmid:1293322
Taniguchi H et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF prior to and in the early stages of pregnancy in rats]. 1992 J Toxicol Sci pmid:1293323
Taniguchi H et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF during the period of fetal organogenesis in rats]. 1992 J Toxicol Sci pmid:1293324
Aso S et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--teratogenicity study in rabbits by subcutaneous administration]. 1992 J Toxicol Sci pmid:1293325
Taniguchi H et al. [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study of subcutaneous administration of PNF during the perinatal and lactation periods in rats]. 1992 J Toxicol Sci pmid:1293326
Otsuka M et al. [Mutagenicity studies of prednisolone farnesylate (PNF)]. 1992 J Toxicol Sci pmid:1293327
Uchiyama H et al. [Effects of prednisolone farnesylate (PNF) gel on skin and ocular mucosa]. 1992 J Toxicol Sci pmid:1293328
Okazaki S et al. [A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks]. 1992 J Toxicol Sci pmid:1293330
Okazaki S et al. [A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks]. 1992 J Toxicol Sci pmid:1293331
Radetich B and Corey EJ A general stereocontrolled, convergent synthesis of oligoprenols that parallels the biosynthetic pathway. 2002 J. Am. Chem. Soc. pmid:11890779
Clarke HC et al. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. 2003 J. Am. Soc. Nephrol. pmid:12660318
Williams JM and Savage CO Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. 2005 J. Am. Soc. Nephrol. pmid:15548565
Nozawa Y et al. Stachybotrin C and parvisporin, novel neuritogenic compounds. II. Structure determination. 1997 J. Antibiot. pmid:9315075
Cerca N et al. Farnesol induces cell detachment from established S. epidermidis biofilms. 2013 J. Antibiot. pmid:23549353
Kaneko M et al. Effect of farnesol on mevalonate pathway of Staphylococcus aureus. 2011 J. Antibiot. pmid:21772307
Koo H et al. Inhibition of Streptococcus mutans biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. 2003 J. Antimicrob. Chemother. pmid:14563892

Table of Content